Tests dapagliflozin to limit heart damage after a heart attack
Tests dapagliflozin against placebo in adults with ST elevation heart attack.
Plain-language title generated from the registry record
Registry title: Dapagliflozin in STEMI
Key facts
- Where
- Ottawa, CanadaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults having a serious heart attack (STEMI) who are sent for an emergency procedure to open the blocked artery (PPCI). It tests whether dapagliflozin (an SGLT2i) or a placebo limits heart damage, measured by heart MRI (CMR).
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- STEMI heart attack with chest pain for at least 30 minutes, starting 12 hours or less before entering the study. The ECG must show a high-risk pattern (large anterior STEMI or extensive non-anterior STEMI).
- Earlier treatment
- Cannot have taken an SGLT2i in the last 8 weeks.
- Biomarker or test result
- A 12-lead ECG with ST-segment elevation: at least 2mm in each of at least 2 neighbouring chest leads (V1-V6) for anterior STEMI, or the extensive non-anterior pattern described in the criteria.
Main reasons for not taking part
- Cannot have heart MRI (CMR)
- Cardiogenic shock on arrival (Killip 4)
- Type 1 diabetes
- Pregnant or nursing
- Previous heart attack
Read by machine on 9 November 2026.
Where in Canada
- University of Ottawa Heart InstituteOttawa, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ottawa Heart Institute Research Corporation
- Trial code
- NCT06174753
- Record updated
- 20 February 2026
- Original description
The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI.Read full original descriptionShow less
The University of Ottawa Dapagliflozin in STEMI Randomized Clinical Trial
The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI.
Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo.
Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.
Inclusion: Patients referred for PPCI meeting the following criteria are eligible for the study:; Ischemic chest discomfort of ≥30 minutes duration, and; Onset of chest pain ≤12 hours prior to entry into the study, and; One of the following High-Risk criteria on a standard 12 lead ECG:; Anterior STEMI with ST-segment elevation ≥2mm (0.2 mV) in each of at least 2 contiguous precordial leads (V1-V6) b. Extensive non-anterior STEMI defined as ST-segment elevation of >1mm in two or more contiguous non-anterior leads accompanied by i. 8 or more leads with > 1 mm ST elevation or depression, or both; OR ii. Sum of ST- segment elevation >20mm.
Exclusion: Therapy with SGLT2i within last 8 weeks; Chronic symptomatic HF with prior hospitalization for HF within the last year; Known history of prior MI; Previous randomization in the present study; Participation in a study with another investigational device or drug < four weeks; Type 1 diabetes mellitus; Any non-CV condition with a life expectancy of less than one year; Known severe hepatic impairment (Cirrhosis); Known severe valvular heart disease; Severe renal impairment (eGFR < 30 mL/min1.73m2 (based on prior or baseline blood work); Age < 18 years; Any contraindication to undergo CMR imaging; Killip 4 (Cardiogenic shock on presentation); Pregnancy; Nursing mother; Unwilling to use appropriate forms of contraception, as applicable; hospitalization; Inability to provide informed consent; Confirmed ketoacidosis at time of admission; Need for CABG within 90 days based on the results of the initial coronary angiogram; False positive STEMI (based on the results of the coronary angiogram).